• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sanofi

    2/14/22 1:29:58 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    SC 13G 1 d308063dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 0)*

     

     

    Sanofi

    (Name of Issuer)

    Ordinary Shares and American Depositary Shares

    (Title of Class of Securities)

    80105N105

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 80105N105   13G   PAGE 2 OF 4 PAGES

     

      1   

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Dodge & Cox    94-1441976

      2   

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  ☐        (b)  ☐

     

    N/A

      3   

    SEC USE ONLY

     

      4   

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California - U.S.A.

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

          5     

    SOLE VOTING POWER

     

    24,109,804 Ordinary Shares and 88,784,333 American Depositary Shares

          6   

    SHARED VOTING POWER

     

    0

          7   

    SOLE DISPOSITIVE POWER

     

    24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

          8   

    SHARED DISPOSITIVE POWER

     

    0

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

    10   

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

    N/A

    11   

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.6%

    12  

    TYPE OF REPORTING PERSON*

     

    IA

     


    Item 1(a)

    Name of Issuer:

    Sanofi

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    54 Rue La Boetie

    Paris, France 75008

     

    Item 2(a)

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b)

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c)

    Citizenship:

    California - U.S.A.

     

    Item 2(d)

    Title of Class of Securities:

    Ordinary Shares and American Depositary Shares

     

    Item 2(e)

    CUSIP Number:

    80105N105

     

    Item 3

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

    (e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

     

      (b)

    Percent of Class:

    5.6%


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    24,109,804 Ordinary Shares and 88,784,333 American Depositary Shares

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of:

    24,109,804 Ordinary Shares and 93,402,049 American Depositary Shares

     

      (iv)

    shared power to dispose or to direct the disposition of:

    0

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, Sanofi.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2022                

     

    DODGE & COX
    By:  

    /S/ Katherine M. Primas

    Name:   Katherine M. Primas
    Title:   Chief Compliance Officer
    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings